Mutational analysis of CFTR in the Ecuadorian population using next-generation sequencing

被引:8
|
作者
Carlos Ruiz-Cabezas, Juan [1 ,2 ,3 ]
Barros, Francisco [4 ]
Sobrino, Beatriz [4 ]
Garcia, Gustavo [1 ,3 ,5 ]
Burgos, Ramiro [3 ]
Farhat, Carlos [1 ]
Castro, Antonella [1 ]
Munoz, Lenin [1 ]
Karina Zambrano, Ana [6 ]
Martinez, Mariela [7 ]
Montalvan, Martha [1 ,8 ,9 ]
Paz-y-Mino, Cesar [6 ]
机构
[1] UEES, Guayaquil, Ecuador
[2] Univ Catolica Santiago Guayaquil, Inst Invest Integral Salud ISAIN UCSG, Guayaquil, Ecuador
[3] Inst Oncologico Nacl Soc Lucha Canc ION SOLCA, Guayaquil, Ecuador
[4] Fdn Publ Galega Med Xenom SERGAS, CIBERER, Grp Med Xenorn USC, Santiago De Compostela, Spain
[5] Univ Catolica Santiago Guayaquil, Escuela Odontol, Guayaquil, Ecuador
[6] Univ UTE, Fac Ciencias Salud, Ctr Invest Genet & Genom, Quito, Ecuador
[7] Fdn Fibrosis Quist, Guayaquil, Ecuador
[8] Univ Guayaquil, Fac Ciencias Med, Guayaquil, Ecuador
[9] Univ Catolica Santiago Guayaquil, Fac Ciencias Med, Guayaquil, Ecuador
关键词
CFTR variants; CF in Ecuador; NGS; Microarrays; CYSTIC-FIBROSIS PATIENTS; GENE; SPECTRUM; FRAMEWORK; PHENOTYPE; ADMIXTURE; VARIANTS;
D O I
10.1016/j.gene.2019.02.015
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The frequency distributions of cystic fibrosis variants are heterogeneous in Ecuador because of the genetic admixture of its population. The aim of this study was to identify disease-causing variants among Ecuadorian cystic fibrosis (CF) patients by next-generation sequencing (NGS) of the entire cystic fibrosis transmembrane conductance regulator (MR) gene. The results showed an approximation of the frequencies of pathogenic variants in the population under study and an optimal mutation panel for routine first-line CF molecular diagnosis. One hundred and forty-one patients with suspected CF from the 3 largest Ecuadorian cities (Guayaquil, Quito, and Cuenca) were studied. One hundred and seventy mutated alleles were detected in eighty-five individuals. Twenty-eight disease-causing variants were identified, with p.Phe508del and p.His609Arg being the most frequent (both 24.7%) followed by p.Gly85Glu (11.1%), p.Leul5Pro (9.4%), p.Asn1303Lys (4.1%), and p.G1y542* (2.3%). Together, these variants constituted 76.44% of the detected disease-causing variants. The following six novel potentially disease-associated variants were detected: 3 deletions (CFTR_dele10, CFTR_dele12, and c.2672delA), 1 nonsense variant (p.Cys491*), 1 missense variant (p.Trp496Arg), and 1 complex allele (p. [Gly253Arg;Gly451Val]). The remaining mutations occurred in isolation and were present in the databases.
引用
收藏
页码:28 / 32
页数:5
相关论文
共 50 条
  • [41] Multi-Gene Mutational Profiling of Lung Carcinoma Using Next-Generation Sequencing (NGS)
    Chowdhuri, S. Roy
    Routbort, M.
    Patel, K. P.
    Kanagal-Shamanna, R.
    Singh, R.
    Simon, G.
    Broaddus, R.
    Aldape, K.
    Luthra, R.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (06): : 922 - 922
  • [42] Sporadic and Familial Congenital Cataracts: Mutational Spectrum and New Diagnoses Using Next-Generation Sequencing
    Ma, Alan S.
    Grigg, John R.
    Ho, Gladys
    Prokudin, Ivan
    Farnsworth, Elizabeth
    Holman, Katherine
    Cheng, Anson
    Billson, Frank A.
    Martin, Frank
    Fraser, Clare
    Mowat, David
    Smith, James
    Christodoulou, John
    Flaherty, Maree
    Bennetts, Bruce
    Jamieson, Robyn V.
    [J]. HUMAN MUTATION, 2016, 37 (04) : 371 - 384
  • [43] APPLICATIONS OF NEXT-GENERATION SEQUENCING Sequencing technologies - the next generation
    Metzker, Michael L.
    [J]. NATURE REVIEWS GENETICS, 2010, 11 (01) : 31 - 46
  • [44] Mutational Profiling of Anaplastic Thyroid Carcinoma Using Targeted Next-Generation Sequencing in a Large Cohort
    Hosseini, Sayed M.
    Zafereo, Mark E.
    Cabanillas, Maria E.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (06): : S58 - S58
  • [45] Resolving Discrepancies in Idylla BRAF Mutational Assay Results Using Targeted Next-Generation Sequencing
    George, Giby V.
    Liu, Huijie
    Jajosky, Audrey N.
    Oltvai, Zoltan N.
    [J]. GENES, 2024, 15 (05)
  • [46] Mutational Analysis of Myeloid Neoplasms in Paired Peripheral Blood and Bone Marrow by Next-generation Sequencing
    Michaels, P.
    Kim, A.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2018, 20 (06): : 921 - 922
  • [47] Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma
    Cornejo, Kristine M.
    Cosar, Ediz F.
    Paner, Gladell P.
    Yang, Ping
    Tomaszewicz, Keith
    Meng, Xiuling
    Mehta, Vikas
    Sirintrapun, Sahussapont Joseph
    Barkan, Guliz A.
    Hutchinson, Lloyd
    [J]. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2020, 28 (01) : 51 - 59
  • [48] Ultrasensitive mutational analysis in cell-freeDNA by targeted next-generation sequencing with molecular tags
    Tam, Nga Wan Rachel
    Diala, Irmina
    Chen, Xiaoji
    Darbonne, Walter
    [J]. CANCER RESEARCH, 2017, 77
  • [49] Validation of a semiconductor next-generation sequencing assay for the clinical genetic screening of CFTR
    Trujillano, Daniel
    Weiss, Maximilian E. R.
    Koester, Julia
    Papachristos, Efstathios B.
    Werber, Martin
    Kandaswamy, Krishna Kumar
    Marais, Anett
    Eichler, Sabrina
    Creed, Jenny
    Baysal, Erol
    Jaber, Iqbal Yousuf
    Mehaney, Dina Ahmed
    Farra, Chantal
    Rolfs, Arndt
    [J]. MOLECULAR GENETICS & GENOMIC MEDICINE, 2015, 3 (05): : 396 - 403
  • [50] Interrogating Pharmacogenetics Using Next-Generation Sequencing
    Ji, Yuan
    Shaaban, Sherin
    [J]. JOURNAL OF APPLIED LABORATORY MEDICINE, 2024, 9 (01): : 50 - 60